The US policy action blueprint, accompanying situation analysis report and supporting materials were developed in collaboration with a US Expert Advisory Group. The multidisciplinary group had full editorial control over the content of these materials, which reflect group consensus. All members provided their time for free.

We would like to thank group members for their contribution:

Advisory Group US Radioligand Therapy Readiness Assessment Framework
Josh Mailman

Josh Mailman

President, Northern California CarciNET Community


Dr Ronald D. Ennis, FASTRO

Vice Chairman for Network Integration and Quality, Medical Director of Clinical Network for Radiation Oncology, Rutgers Cancer Institute of New Jersey

Peter Friend

Peter M. Friend, LFACHE

Managing Director, Berkeley Research Group; Director NFP Insurance Solutions

Leo Gordon

Dr Leo I. Gordon, FACP

Professor of Medicine, Co-Director, Hematologic Malignancies Program, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Suzanne Lapi

Professor Suzanne Lapi

Vice Chair of Translational Research, Department of Radiology, The University of Alabama at Birmingham

Daniel Lee

Dr Daniel J. Lee

Section Chief, Nuclear Medicine, Ochsner Medical Center

Erik Mittra

Dr Erik Mittra

Professor of Diagnostic Radiology, Chief of Nuclear Medicine & Molecular Imaging, Oregon Health & Science University

Todd Morgan

Dr Todd M. Morgan

Professor, Chief of Division of Urologic Oncology, University of Michigan

Michael Morris

Dr Michael J. Morris

Prostate Cancer Section Head, Memorial Sloan Kettering Cancer Center

Thomas Paivanas

Thomas A. Paivanas, MHSA

Executive Director, The CUSP Group, LLC

Jonathan Strosberg

Professor Jonathan Strosberg

Neuroendocrine Tumor Division Head, Chair of the Department of Gastrointestinal Oncology Research Program, Moffitt Cancer Center

Get in touch

For more information about this project contact us:

We’re on Twitter! Follow @radioligand¬†for updates on this project and other exciting developments in targeted cancer care.